Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing

16 Mar 2016

Abstract excerpt

Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested - inhibition of angiogenesis - has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Prostate Cancer Treatment and Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26995304
DOI: 10.1016/j.phrs.2016.03.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicingPMID 26995304Read ↗

Gene variants in the angiogenesis pathway and prostate cancer.Semantic proximity Read ↗

Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials.Semantic proximity Read ↗

VEGF Spliced Variants: Possible Role of Anti-Angiogenesis TherapySemantic proximity Read ↗

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer ProgressionSemantic proximity Read ↗

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanomaSemantic proximity Read ↗

Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasionSemantic proximity Read ↗

Polymorphisms in angiogenesis-related genes and prostate cancer.Semantic proximity Read ↗

Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR systemSemantic proximity Read ↗

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.Semantic proximity Read ↗

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.Semantic proximity Read ↗

MST1 is downregulated and acts as a tumor suppressor in prostate cancerSemantic proximity Read ↗

SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.